Cart
0
Get 20% Free Customization In This Report
Buy this report from - $3456

Diabetes Therapeutics Market by Product [Injectables (Insulin, Glucagon-like Peptide-1 (GLP-1) Receptor Agonists, and Amylinomimetic Drugs) and Oral-antidiabetic Drugs (OAD) (Biguanides, Sulfonylureas, Thiazolidinediones, Alpha-glucosidase Inhibitors, Dipeptidyl Peptidase IV (DPP-4) Inhibitors, Meglitinides, and Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors)] - Global Opportunity Analysis and Industry Forecast, 2017-2023

LI_173542
Pages: 170
Aug 2017 | 1460 Views
face gplus_n
Author's : Amrita Srivastava and Pallavi Jaiswal
Tables: 24
Charts: 39
twit_n pr_n

Diabetes Therapeutics Market Overview:

Global Diabetes Therapeutics Market was valued at $66,993 million in 2016, and is estimated to reach $186,842 million by 2023, growing at a CAGR of 16.0% from 2017 to 2023. Diabetes therapeutics are drugs used by diabetics to maintain the blood glucose levels to restore the blood glucose metabolism to a normal state.

The factors that drive the global diabetes therapeutics market include rise in geriatric population and increase in prevalence of diabetes worldwide due to increased obesity, urbanization, poor diet, and substandard healthcare conditions in some developing and underdeveloped countries. Moreover, the development of affordable & effective diabetes therapeutics, growth in awareness among people about self-management of diabetes, and support from the government further boost the market growth. However, side effects of diabetic drugs and stringent approval process for drugs restrain this growth. Rise in awareness about diabetes care and untapped market opportunities in developing regions are expected to provide numerous opportunities for market development.

Diabetes Therapeutics Market Segmentation

Diabetes Therapeutics Market Segmentation

Segment Review

The injectable segment witnessed rapid growth due to rise in prevalence of diabetes, increase in geriatric population, and high demand for self-care. Moreover, injectable can be used for both type-I and type-II diabetes, whereas OAD are used majorly for type-II diabetes. In addition, there is increased awareness about use of insulin (one of the injectable) as an anti-diabetic drug. Therefore, adoption of insulin is high in most of the regions of the world, which is expected to stimulate the growth of this segment.

Diabetes Therapeutics Market, By Product, 2016 (%)

Diabetes Therapeutics Market, By Product, 2016

Snapshot of LAMEA Diabetes Therapeutics Market

According to IDF seventh Edition, about 29.6 million of the adult population in the South and Central America regions suffered from diabetes in 2015, of which, about 39.0% of them were undiagnosed. The presence of large number of people with diabetes in this region and developing healthcare facilities are expected to fuel the market growth.

According to the United Nations World Population Ageing Report, around 64.4 million people in Africa and 70.9 million people in Latin America and Caribbean belonged to the age group of 60 years and above in 2015. In addition, purchasing power has increased in this region, which fuels the market growth. Moreover, government organizations in this region focus to improve the healthcare infrastructure by increased funding, which boosts the growth further.

Saudi Arabia Diabetes Therapeutics Market, 2016-2023 ($Million)

Saudi Arabia Diabetes Therapeutics Market, 2016-2023

The list of key players profiled in this report include AstraZeneca plc, Boehringer Ingelheim GmbH, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Novo Nordisk, Sanofi S.A., and Takeda Pharmaceutical Company Limited.

Key players in the value chain include Astellas Pharma Inc., Biocon Limited, Diasome Pharmaceuticals, Inc., Generex Biotechnology Corp., MannKind Corporation, and Pfizer Inc.

Key Benefits

  • The study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.
  • It offers information about the current and upcoming trends in the market from 2016 to 2023 to determine the prevailing opportunities.
  • Comprehensive analysis of factors that drive and restrict the market growth is provided.
  • Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global and regional scale are provided.
  • Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.

Diabetes Therapeutics Market Key Segments:

By Product

  • Injectables
    • Insulin
    • Glucagon-like Peptide-1 (GLP-1) Receptor Agonists/Incretin Mimetics
    • Amylin Analogue/Amylinomimetic Drugs
  • Oral-antidiabetic Drugs (OAD)
    • Biguanides
    • Sulfonylureas
    • Thiazolidinediones
    • Alpha-glucosidase Inhibitors
    • Dipeptidyl Peptidase IV (DPP-4) Inhibitors/Gliptins
    • Meglitinides
    • Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors/Gliflozins

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.2.2.1. Competitive intelligence of companies and their strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. MARKET DYNAMICS

3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.4.4. Impact analysis

3.5. CLINICAL TRIALS

Chapter: 4 GLOBAL DIABETES THERAPEUTICS MARKET, BY PRODUCT

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. INJECTABLES

4.2.1. Insulin

4.2.1.1. Market size and forecast

4.2.2. Glucagon-like peptide-1 (GLP-1) receptor agonists

4.2.2.1. Market size and forecast

4.2.3. Amylinomimetic drug

4.2.3.1. Market size and forecast

4.2.4. Key market trends
4.2.5. Growth factors and opportunities
4.2.6. Market size and forecast

4.3. ORAL-ANTIDIABETIC DRUGS (OAD)

4.3.1. Biguanides

4.3.1.1. Market size and forecast

4.3.2. Sulfonylureas

4.3.2.1. Market size and forecast

4.3.3. Thiazolidinediones

4.3.3.1. Market size and forecast

4.3.4. Alpha-glucosidase inhibitors

4.3.4.1. Market size and forecast

4.3.5. Dipeptidyl Peptidase IV (DPP-4) inhibitors

4.3.5.1. Market size and forecast

4.3.6. Meglitinides

4.3.6.1. Market size and forecast

4.3.7. Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors

4.3.7.1. Market size and forecast

4.3.8. Key market trends
4.3.9. Growth factors and opportunities
4.3.10. Market size and forecast

Chapter: 5 DIABETES THERAPEUTICS MARKET, BY REGION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. NORTH AMERICA

5.2.1. Key market trends
5.2.2. Key growth factors and opportunities
5.2.3. Market size and forecast
5.2.4. U.S.
5.2.5. Canada
5.2.6. Mexico

5.3. EUROPE

5.3.1. Key market trends
5.3.2. Key growth factors and opportunities
5.3.3. Market size and forecast
5.3.4. Germany
5.3.5. France
5.3.6. UK
5.3.7. Italy
5.3.8. Spain
5.3.9. Rest of Europe

5.4. ASIA-PACIFIC

5.4.1. Key market trends
5.4.2. Key growth factors and opportunities
5.4.3. Market size and forecast
5.4.4. Japan
5.4.5. China
5.4.6. India
5.4.7. Australia
5.4.8. South Korea
5.4.9. Rest of Asia-Pacific

5.5. LAMEA

5.5.1. Key market trends
5.5.2. Key growth factors and opportunities
5.5.3. Market size and forecast
5.5.4. Brazil
5.5.5. South Africa
5.5.6. Saudi Arabia
5.5.7. Rest of LAMEA

Chapter: 6 COMPANY PROFILES

6.1. ASTRAZENECA PLC

6.1.1. Company overview
6.1.2. Operating business segments
6.1.3. Business performance
6.1.4. Key strategic moves and developments

6.2. BOEHRINGER INGELHEIM GMBH

6.2.1. Company overview
6.2.2. Operating business segments
6.2.3. Business performance
6.2.4. Key strategic moves and developments

6.3. ELI LILLY AND COMPANY

6.3.1. Company overview
6.3.2. Operating business segments
6.3.3. Key strategic moves and developments

6.4. GLAXOSMITHKLINE PLC

6.4.1. Company overview
6.4.2. Operating business segments
6.4.3. Business performance
6.4.4. Key strategic moves and developments

6.5. JOHNSON & JOHNSON

6.5.1. Company overview
6.5.2. Operating business segments
6.5.3. Business performance
6.5.4. Key strategic moves and developments

6.6. MERCK & CO., INC.

6.6.1. Company overview
6.6.2. Operating business segments
6.6.3. Business performance
6.6.4. Key strategic moves and developments

6.7. NOVARTIS AG

6.7.1. Company overview
6.7.2. Operating business segments
6.7.3. Business performance
6.7.4. Key strategic moves and developments

6.8. NOVO NORDISK

6.8.1. Company overview
6.8.2. Operating business segments
6.8.3. Business performance
6.8.4. Key strategic moves and developments

6.9. SANOFI S.A.

6.9.1. Company overview
6.9.2. Operating business segments
6.9.3. Business performance
6.9.4. Key strategic moves and developments

6.10. TAKEDA PHARMACEUTICAL COMPANY LIMITED

6.10.1. Company overview
6.10.2. Operating business segments
6.10.3. Business performance
6.10.4. Key strategic moves and developments

LIST OF TABLES

TABLE 1. GLOBAL DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 2. GLOBAL INJECTABLE DIABETES THERAPEUTICS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 3. DIABETES INJECTABLE THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 4. GLOBAL OAD DIABETES THERAPEUTICS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 5. GLOBAL OAD DIABETES THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 6. DIABETES THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 7. NORTH AMERICA DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 8. NORTH AMERICA DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 9. EUROPE DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 10. EUROPE DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 11. ASIA-PACIFIC DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 12. ASIA-PACIFIC DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 13. LAMEA DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 14. LAMEA DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 15. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 16. BOEHRINGER: COMPANY SNAPSHOT
TABLE 17. ELI LILLY: COMPANY SNAPSHOT
TABLE 18. GLAXOSMITHKLINE: COMPANY SNAPSHOT
TABLE 19. J&J: COMPANY SNAPSHOT
TABLE 20. MERCK: COMPANY SNAPSHOT
TABLE 21. NOVARTIS: COMPANY SNAPSHOT
TABLE 22. NOVO NORDISK: COMPANY SNAPSHOT
TABLE 23. SANOFI: COMPANY SNAPSHOT
TABLE 24. TAKEDA: COMPANY SNAPSHOT

LIST OF FIGURES

FIGURE 1. DIABETES THERAPEUTICS MARKET SEGMENTATION
FIGURE 2. TOP INVESTMENT POCKETS
FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, (2014-2016)
FIGURE 4. TOP WINNING STRATEGIES: NATURE AND TYPE
FIGURE 5. TOP COMPANIES AND THEIR STRATEGIES
FIGURE 6. DETAILED STRUCTURE OF COMPANIES AND NATURE OF STRATEGIES
FIGURE 7. DETAILED STRUCTURE OF COMPANIES AND TYPE OF STRATEGIES
FIGURE 8. MARKET SHARE ANALYSIS, DIABETES THERAPEUTICS MARKET, 2016
FIGURE 9. IMPACT ANALYSIS: DIABETES THERAPEUTICS MARKET
FIGURE 10. TOTAL NUMBER OF CLINICAL TRIALS IN DIABETES THERAPEUTICS MARKET
FIGURE 11. INSULIN MARKET, 2016-2023, ($MILLION)
FIGURE 12. GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS/INCRETIN MIMETICS MARKET, 2016-2023, ($MILLION)
FIGURE 13. AMYLIN ANALOGUE/AMYLINOMIMETIC DRUG MARKET, 2016-2023, ($MILLION)
FIGURE 14. BIGUANIDES MARKET, 2016-2023, ($MILLION)
FIGURE 15. SULFONYLUREAS MARKET, 2016-2023, ($MILLION)
FIGURE 16. THIAZOLIDINEDIONES MARKET, 2016-2023, ($MILLION)
FIGURE 17. ALPHA-GLUCOSIDASE INHIBITORS MARKET, 2016-2023, ($MILLION)
FIGURE 18. DIPEPTIDYL PEPTIDASE IV (DPP-4) INHIBITORS /GLIPTINS MARKET, 2016-2023, ($MILLION)
FIGURE 19. MEGLITINIDES MARKET, 2016-2023, ($MILLION)
FIGURE 20. SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS /GLIFLOZINS MARKET, 2016-2023, ($MILLION)
FIGURE 21. U.S. DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 22. CANADA DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 23. MEXICO DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 24. GERMANY DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 25. FRANCE DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 26. UK DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 27. ITALY DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 28. SPAIN DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 29. REST OF EUROPE DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 30. JAPAN DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 31. CHINA DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 32. INDIA DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 33. AUSTRALIA DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 34. SOUTH KOREA DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 35. REST OF ASIA-PACIFIC DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 36. BRAZIL DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 37. SOUTH AFRICA DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 38. SAUDI ARABIA DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)
FIGURE 39. REST OF LAMEA DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)

 

The global diabetes therapeutics market is expected to increase in the near future, owing to high prevalence of diabetes, growth in geriatric population, development of affordable & effective diabetes therapeutics, and changes in lifestyle of people leading to diabetes.

Diabetes drugs have gained popularity among patients and healthcare providers, owing to the benefits associated with them, and ease of use when compared to alternative diabetes therapies.

However, there can be adverse effects of some of these drugs in few patients, which restrain the market growth. Asia-Pacific and LAMEA are expected to offer lucrative opportunities to market players throughout the forecast period. North America is expected to dominate the global diabetes therapeutics market in the near future, followed by Europe.

 

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

 
 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 
 

Purchase Full Report of
Diabetes Therapeutics Market- Global Opportunity Analysis and Industry Forecast, 2017-2023

  • Online Only
  • $3456
  • Online cloud Access only
  • Restected Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $3840
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5370
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6450
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprice
    License/PDF

  • $8995
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  • Free quartery industry update
  • Free report update (Within 180 days)
  • Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts